New meningitis vaccine shows promise for infants in landmark trial
NCT ID NCT05794230
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new vaccine (MenACYW) to protect against four types of meningococcal bacteria that can cause meningitis and sepsis. Over 1,500 healthy infants and toddlers in India and South Africa received the vaccine alongside routine childhood shots. Researchers compared its immune response and safety to an existing vaccine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Meningococcal conjugate vaccine (MenACYW)
What this could lead to
If successful, this could provide a safe and effective option to protect infants and toddlers against four types of meningococcal disease.
What could go wrong
This trial is already completed, but results may not apply to all populations or settings. Side effects like injection site reactions or fever are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 3560001
Pune, 411043, India
-
Investigational Site Number : 3560002
Pune, 411011, India
-
Investigational Site Number : 3560003
New Delhi, 110002, India
-
Investigational Site Number : 3560004
Mysore, 570004, India
-
Investigational Site Number : 3560006
Chennai, 603203, India
-
Investigational Site Number : 3560007
Hyderabad, 500018, India
-
Investigational Site Number : 3560009
Kolkata, 700017, India
-
Investigational Site Number : 3560011
Manipal, 576104, India
-
Investigational Site Number : 3560013
Mysore, 570001, India
-
Investigational Site Number : 3560016
Kanpur, 208002, India
-
Investigational Site Number : 7100001
Middelburg, 1055, South Africa
-
Investigational Site Number : 7100002
Cape Town, 7505, South Africa
-
Investigational Site Number : 7100003
Cape Town, 7937, South Africa
-
Investigational Site Number : 7100005
Johannesburg, 2013, South Africa
-
Investigational Site Number : 7100006
George, 6530, South Africa